**The** **Japanese Society of Autologous Blood Transfusion**

**様式２－B**

**Journal of Japanese Society of Autologous Blood Transfusion Potential Conflict of Interest Disclosure Statement**

Author’s name:

Manuscript Title:

(All authors are required to disclose any COI within the period of 24 months prior to the submission of any manuscript in the subject matter of which any company, entity, or organization has an interest)

|  |  |  |
| --- | --- | --- |
| Area | Yes or No | If Yes, list the name(s) of author(s) and commercial entity(ies) |
| 1. Employment/Leadership position/Advisory role  1,000,000 yen or more annually from one commercial entity | Yes/No | e.g. Taro Nihon, Atlantic Ocean Pharmaceuticals  Takashi Fujiyama, ABC Pharmaceuticals |
| 2. Stock ownership or options  Profit of1,000,000 yen or more annually from the stock of one company/ownership of 5% or more of total shares of one company | Yes/No |  |
| 3. Patent royalties/licensing fees  1,000,000 yen or more per one royalty/licensing fee annually | Yes/No |  |
| 4. Honoraria (e.g. lecture fees)  1,000,000 yen or more annually from one commercial entity | Yes/No |  |
| 5. Manuscript fees  500,000 yen or more annually from one commercial entity | Yes/No |  |
| 6. Research funding  2,000,000 yen or more annual payment to departments (department, field, or laboratory) who share research expenses from the same commercial entity. | Yes/No |  |
| 7. Subsidies or Donations  2,000,000 yen or more annual payment to departments (department, field, or laboratory) who share subsidies or donations from the same commercial entity. | Yes/No |  |
| 8. Endowed departments by commercial entities  (If any of the authors belongs to an endowed department sponsored by any commercial entity) | Yes/No |  |
| 9. Travel fees, gifts, and others  50,000 yen or more annually from one commercial entity | Yes/No |  |

This statement will be kept for 2 years after the publication of the manuscript.

Date of Completion YYYY MM DD

Corresponding author's signature